GRCE vs USB · $35.0M cap vs P/E 12, rev $28.66B
Grace Therapeutics, Inc. (GRCE) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
GRCE does not have a complete income-statement cache yet.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
GRCE currently screens at market cap $35.0M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the GRCE and USB stock pages for the full models.
Not investment advice.